eNewsroom for: Biogen Idec

http://pressreleaseheadlines.com/wp-content/Cimy_User_Extra_Fields/Biogen Idec/Screen Shot 2013-04-16 at 4.47.03 PM.png

Biogen Idec Company Profile

In a word, Biogen Idec Hemophilia is dedicated. We're dedicated to improving the lives of people with hemophilia and dedicated to the community in which our team is so deeply rooted. For our team members our commitment is personal; many of us have devoted our careers to advancing hemophilia care. We bring years of experience from many different sectors of the community: factor manufacturers, advocacy organizations, and hemophilia treatment centers, to name just a few. Our parent company, Biogen Idec, has been developing innovative therapies for people with chronic conditions for more than 30 years. Biogen Idec Hemophilia has combined this long-standing tradition of excellence with a team deeply rooted in the hemophilia community to develop our next innovation—long-lasting clotting factors. Our vision for the future of hemophilia treatment has attracted a number of leaders from the hemophilia community, such as Glenn Pierce, MD, PhD, former President of the National Hemophilia Foundation. Dr Pierce is the Chief Medical Officer for Biogen Idec Hemophilia and Senior Vice President of Global Medical Affairs for all of Biogen Idec.

News from Biogen Idec:

American Management Association Teams With Biogen Idec To Create Life Skills Workshops For People Living With Hemophilia

NEW YORK, April 17, 2013 /PRNewswire/ — Programs provide practical life skills tools to help people with inherited bleeding disorders live life on their own terms World Hemophilia Day is April 17 AMA Enterprise, a division of American Management Association, has partnered with Biogen Idec, a global research-based biotechnology company, to develop a series of […]